News - Daily Reporter

Johnson_Pres_12.09

12 Sept 2022

Sotorasib improves PFS versus docetaxel in patients with pre-treated KRAS G12C-mutated NSCLC

Read more

Ming Lee_Pres_12.09

12 Sept 2022

Could anti-PD-L1 be the best choice as front-line therapy in platinum-ineligible patients with NSCLC?

Read more

Komal Jhaveri_Dev_12.09

12 Sept 2022

Antibody–drug conjugates show potential in advanced solid tumours

Read more

Session_generic

12 Sept 2022

NECs: mixed results for second-line therapy after progression

Read more

Delegates_generic

12 Sept 2022

The first randomised study of peptide receptor radionuclide therapy in pancreatic NETs met its primary endpoint

Read more

Venue_speaker on camera

12 Sept 2022

Nivolumab shows encouraging efficacy in high-risk patients with precancerous oral lesions

Read more

Garon_PP_lung_11.09

11 Sept 2022

Lack of clinical benefit with adjuvant canakinumab in completely resected NSCLC  

Read more

Bardia_PP_11.09

11 Sept 2022

PRO data support the use of antibody–drug conjugates in metastatic breast cancer

Read more

Kasper_Presidential I_10.09

10 Sept 2022

First positive phase III data for a gamma secretase inhibitor in desmoid tumours

Read more

Public_generic

10 Sept 2022

Next-generation sequencing can identify molecular alterations in glioma: are we ready for targeted treatments?

Read more

Curioni_MO immuno_10.09

10 Sept 2022

Phase I studies provide further data on the use of T-cell based therapies in solid tumours

Read more

Venue_flags_ESMO 2022

10 Sept 2022

The CXCR2 antagonist AZD5069 plus enzalutamide is shown to be active in mCRPC

Read more

Topics

Lung and other thoracic tumours ESMO Congress 2022 Anticancer agents & Biologic therapy Endocrine and neuroendocrine tumours Head and neck cancers Breast Cancer Sarcomas Central nervous system malignancies Personalised medicine Cancer Immunology and Immunotherapy Genitourinary cancers Gynaecologic malignancies Melanoma and other skin tumours

Latest content

Parker_Pres.12.09

12 Sept 2022

Prostate cancer: data support adding ADT for patients undergoing post-operative radiotherapy

Read more

Ming Lee_Pres_12.09

12 Sept 2022

Could anti-PD-L1 be the best choice as front-line therapy in platinum-ineligible patients with NSCLC?

Read more

Chouieri_Pres_12.09

12 Sept 2022

First-line triplet of TKI plus dual immunotherapy improves outcomes in renal cell carcinoma

Read more

Johnson_Pres_12.09

12 Sept 2022

Sotorasib improves PFS versus docetaxel in patients with pre-treated KRAS G12C-mutated NSCLC

Read more

Session_generic

12 Sept 2022

NECs: mixed results for second-line therapy after progression

Read more